GU Cast | Urology Podcast – Details, episodes & analysis

World-renowned sexual health expert, Dr Chris Nelson, Chief of Psychology at Memorial Sloan-Kettering Cancer Centre, joins us in studio to run through the new Movember-supported "Guidelines for Sexual Health Care for Prostate Cancer Patients". A really helpful overview and structure for anyone working in this field, and for patients and their loved ones. Chris shares his 20-plus years of experience working in this field at one of the world's premier prostate cancer centres.

Even better on our YouTube channel 

Links:
Movember Sexual Health Guidelines

We recently hosted another live webinar for our Gold Partners, Mundipharma,  this time asking the question, "Is high-risk BCR actually metastatic prostate cancer??". It's a reasonable question! This podcast was anchored from the GU Cast studio in Melbourne by usual hosts, Renu Eapen and Declan Murphy, joined in person by Andrew Loblaw, radiation oncologist from Toronto, and online by medical oncologist Jeff Goh in Brisbane.

Best enjoyed on our YouTube channel if you want to check out the slides. 

Runsheet:

• Is high-risk biochemical recurrence already metastatic prostate cancer?Declan Murphy
• Is the management of high-risk BCR and mHSPC now the same? Jeffrey Goh
• Prostate radiotherapy is the real triplet therapy; plus when should we use SBRT? Andrew Loblaw

Q&A and case discussions

This webinar was organised by our Gold Partners, Mundipharma, who also support GU Cast as Gold Partners through an unrestricted educational grant.

They started off by introducing themselves as The Three Horsemen of the Apocalypse - what could possibly go wrong!! Declan couldn't resist the opportunity to invite three very eminent radiation oncologists into the studio when they all happened to be in Melbourne, even if he was particularly outnumbered while Renu was away! Vedang Murthy (Tata Memorial, India), Andrew Loblaw (Sunnybrook Hospital, Canada), and Sarat Chander (Peter Mac, Melbourne) are all highly specialised in prostate radiation, so Declan invited them into the GU Cast studio to pick their brains on three big areas in prostate radiation:
1. Hypofractionation in 2025 - Who and How?
2. Who needs ADT and for how long when having prostate radiation?
3. Metastasis-directed therapy for oligometastatic disease - is there any point??

Tune in to find out how Urologist Declan Murphy fared up against these three Radiation Oncologists!!! Even better on our YouTube channel

This podcast is supported by our Bronze Partner, Icon Cancer Centre.

SABR supremos Piet Ost and Shankar Siva join us to discuss the management of lymph node-only recurrence following primary treatment of prostate cancer. And of course our resident PSMA PET/CT guru Michael Hofman also turned up as himself and Piet love debating the merits of PSMA!
How and when shoudl we image for biochemical recurrence? What are the limits of SABR? WHat about systemic therapy? It's all in this episode with great leaders in the field.
Recorded on site at Peter Mac on the fringe of the 2023 SABR Symposium. With your usual hosts Renu Eapen and Declan Murphy

Even better on our YouTube channel 

Prof Fred Saad (University of Montreal) drops in to chat about the interesting condition that is non-metastatic castration-resistant prostate cancer (nmCRPC). Which men are at risk of developing metastases? When should we use an AR pathway inhibitor? Why PSMA PET/CT should NOT be used. And hear his thoughts on "dabbling" in prostate cancer!
Also joined by Professor Shankar Siva and Dr Louise Kostos from Peter MacCallum Cancer Centre. Hosted as ever by Dr Renu Eapen and Professor Declan Murphy.
Fred was on a speaker tour in Australia supported by Bayer Pharmaceuticals and this Themed Podcast is supported by Bayer, Silver Partners of GU Cast.
Update  -  we mentioned that darolutamide was the only ARPI listed for reimbursement in Australia (true at time of recording). We can update that all TGA approved ARPIs for nmCRPC are now reimbursed in Australia.

Even better on our YouTube channel

What a great ESMO for GU Oncology!! Declan caught up with some plenary speakers in Madrid to discuss the biggest topics. PSMA theranostics with Louise Emmett (ENZA-P) and Oliver Sartor (PSMAfore); ARPIs in biochemical recurrence with Steve Freedland (EMBARK), Morgan Roupret and Boris Hadaschik. Plus the latest negative immunotherapy trials in prostate cancer with Christian Gratzke.

Even better on our YouTube channel 

The LuTectomy trial has just been published in European Urology, and as the GU Cast team have been very much involved, we thought we should dive into the details on today's podcast. LuTectomy is a clinical trial to evaluate the role of 177-Lutetium-PSMA prior to radical prostatectomy. Declan is the study co-PI along with Professor Michael Hofman, and Renu is first author on the LuTectomy paper (and doing a PhD on it)! Plus, Professor Ken Herrmann from Essen has co-authored the accompanying Editorial in European urology and joins us for a discussion.

Even better on our YouTube channel

Thanks to all the LuTectomy team and to all of our fantastic patients. And huge thanks to our funders.

Funding/Support:
This investigator-initiated study was funded by the Movember Foundation, the Australian Government Medical Research Future Fund (MRFF) with contribution from the EJ Whitten Foundation and Novartis.

Acknowledgements:
We thank the medical, surgical, nursing, nuclear medicine, and administrative staff of all the departments at the Peter MacCallum Cancer Centre who were involved in this trial. We thank the patients who agreed to participate in the study. PSMA-617 was supplied
 by Novartis and no carrier added 177Lu by the Australian Nuclear Science and Technology Organisation (ANSTO).
We remember and thank the late Dr John Violet for his involvement including study conception and design.

Links:
LuTectomy paper in European Urology
LuTectomy Editorial 

One of our most popular episodes in 2022 was "Patting the Hormone Therapy Shark" with author, surfer and prostate cancer survivor, Tim Baker. And a lot has happened in the 12 months since so we invited Tim back for a follow-up chat in this Themed Podcast supported by our GU Cast Gold Partners, Mundipharma.
Tim's inspiring approach to managing the side-effects of androgen deprivation therapy are well worth knowing for anyone involved in advanced prostate cancer including clinicians (especially clinicians!), nurses and allied health care professionals, industry, and of course patients and their loved ones. Tim runs through his "MEDS" strategy in this podcast, and also chats about other options including creative writing, the topic of his ongoing PhD.
Thanks to our friends at Mundipharma for their ongoing support for GU Cast through their Gold Partnership.

Even better on our YouTube channel

Links:
Tim's website
Previous GU Cast episode 

We hijacked our good friends Professor Boris Hadaschik (Urologist, Essen, Germany), and Associate Professor Tyler Seibert (Radiation Oncologist, University of California, San Diego), who happened to be in Melbourne this week, and diverted them into the GU Cast studio for a chat about high-risk prostate cancer. Boris and Tyler were on a speaker tour supported Janssen Pharmaceuticals, so we put together this Themed Podcast supported by Janssen (Gold Partners of GU Cast), to probe three key questions in high-risk prostate cancer in 2023:
1. What is the role of PSMA PET/CT in initial staging?
2. If the PSMA PET/CT is N0, can we avoid pelvic lymph node dissection?
3. What is the optimal radiotherpay strategy for high-risk prostate cancer in 2023?
Superb multidisciplinary chat with two great experts. Thanks to Janssen for their support for this Themed Episode of GU Cast.

Even better on our YouTube channel

Twitter links:
Boris Hadaschik
Tyler Seibert 

The European Association of Nuclear Medicine (EANM) Annual Meeting is the World's leading nuclear medicine extravaganza! Today we cross live to Professor Michael Hofman and friends to hear some of the GU highlights at this year's annual meeting in Vienna.  Michael is joined by Prof Ken Herrmann, Dr Kerry Jewell, Dr Francesco Ceci, Dr Phiilip Kuo, Dr Bastiaan Privé and Dr Wolfgang Fendler. A fantastic update from EANM in Vienna!

Even better on our YouTube channel